Literature DB >> 26559834

Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.

Greg A Kirchenbaum1, Donald M Carter1, Ted M Ross2.   

Abstract

UNLABELLED: Broadly reactive antibodies targeting the conserved hemagglutinin (HA) stalk region are elicited following sequential infection or vaccination with influenza viruses belonging to divergent subtypes and/or expressing antigenically distinct HA globular head domains. Here, we demonstrate, through the use of novel chimeric HA proteins and competitive binding assays, that sequential infection of ferrets with antigenically distinct seasonal H1N1 (sH1N1) influenza virus isolates induced an HA stalk-specific antibody response. Additionally, stalk-specific antibody titers were boosted following sequential infection with antigenically distinct sH1N1 isolates in spite of preexisting, cross-reactive, HA-specific antibody titers. Despite a decline in stalk-specific serum antibody titers, sequential sH1N1 influenza virus-infected ferrets were protected from challenge with a novel H1N1 influenza virus (A/California/07/2009), and these ferrets poorly transmitted the virus to naive contacts. Collectively, these findings indicate that HA stalk-specific antibodies are commonly elicited in ferrets following sequential infection with antigenically distinct sH1N1 influenza virus isolates lacking HA receptor-binding site cross-reactivity and can protect ferrets against a pathogenic novel H1N1 virus. IMPORTANCE: The influenza virus hemagglutinin (HA) is a major target of the humoral immune response following infection and/or seasonal vaccination. While antibodies targeting the receptor-binding pocket of HA possess strong neutralization capacities, these antibodies are largely strain specific and do not confer protection against antigenic drift variant or novel HA subtype-expressing viruses. In contrast, antibodies targeting the conserved stalk region of HA exhibit broader reactivity among viruses within and among influenza virus subtypes. Here, we show that sequential infection of ferrets with antigenically distinct seasonal H1N1 influenza viruses boosts the antibody responses directed at the HA stalk region. Moreover, ferrets possessing HA stalk-specific antibody were protected against novel H1N1 virus infection and did not transmit the virus to naive contacts.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26559834      PMCID: PMC4702689          DOI: 10.1128/JVI.02372-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial.

Authors:  Rebecca J Cox; Gabriel Pedersen; Abdullah S Madhun; Signe Svindland; Marianne Sævik; Lucy Breakwell; Katja Hoschler; Marieke Willemsen; Laura Campitelli; Jane Kristin Nøstbakken; Gerrit Jan Weverling; Jaco Klap; Kenneth C McCullough; Maria Zambon; Ronald Kompier; Haakon Sjursen
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

2.  Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model.

Authors:  Taronna R Maines; Li-Mei Chen; Yumiko Matsuoka; Hualan Chen; Thomas Rowe; Juan Ortin; Ana Falcón; Tran Hien Nguyen; Le Quynh Mai; Endang R Sedyaningsih; Syahrial Harun; Terrence M Tumpey; Ruben O Donis; Nancy J Cox; Kanta Subbarao; Jacqueline M Katz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

3.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

4.  Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.

Authors:  Masanori Terajima; John Cruz; Mary Dawn T Co; Jane-Hwei Lee; Kaval Kaur; Jens Wrammert; Patrick C Wilson; Francis A Ennis
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

5.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

Review 6.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

7.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

Review 8.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

9.  A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.

Authors:  Glendie Marcelin; Rebecca DuBois; Adam Rubrum; Charles J Russell; Janet E McElhaney; Richard J Webby
Journal:  PLoS One       Date:  2011-10-24       Impact factor: 3.240

Review 10.  B cell responses to influenza infection and vaccination.

Authors:  Christopher Chiu; Ali H Ellebedy; Jens Wrammert; Rafi Ahmed
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

View more
  21 in total

Review 1.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

2.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.

Authors:  James D Allen; Hyesun Jang; Joshua DiNapoli; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

4.  Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines.

Authors:  Sinthujan Jegaskanda; Sarah F Andrews; Adam K Wheatley; Jonathan W Yewdell; Adrian B McDermott; Kanta Subbarao
Journal:  JCI Insight       Date:  2019-11-14

5.  Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies.

Authors:  Claudia P Arevalo; Valerie Le Sage; Marcus J Bolton; Theresa Eilola; Jennifer E Jones; Karen A Kormuth; Eric Nturibi; Angel Balmaseda; Aubree Gordon; Seema S Lakdawala; Scott E Hensley
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

6.  Passive immunization with influenza haemagglutinin specific monoclonal antibodies.

Authors:  Rajeev Rudraraju; Kanta Subbarao
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

7.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

8.  Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Scott K Johnson; Michael A Carlock; Greg A Kirchenbaum; James D Allen; Thorsten U Vogel; Simon Delagrave; Joshua DiNapoli; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2017-11-30       Impact factor: 5.103

9.  Computationally Optimized Broadly Reactive H2 HA Influenza Vaccines Elicited Broadly Cross-Reactive Antibodies and Protected Mice from Viral Challenges.

Authors:  Z Beau Reneer; Parker J Jamieson; Amanda L Skarlupka; Ying Huang; Ted M Ross
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

Review 10.  Ferreting Out Influenza Virus Pathogenicity and Transmissibility: Past and Future Risk Assessments in the Ferret Model.

Authors:  Jessica A Belser; Joanna A Pulit-Penaloza; Taronna R Maines
Journal:  Cold Spring Harb Perspect Med       Date:  2020-07-01       Impact factor: 5.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.